Curcumin, one of the natural compounds present in the turmeric rhizomes has been focus of clinical investigations for management of several lifestyle diseases or conditions such as Alzheimer, arthritis, liver disorders, hangovers, inflammation, hypercholesterolemia, allergy, asthma etc. In fact, the Indian ayurvedic system written several centuries ago mentions turmeric for its therapeutic activity in the management of wide variety of diseases.
With the increasing research into biological functions and activities of curcumin, another area of curcumin biology that is gaining lot of attention is its metabolites.
Curcumin C3 Reduct® is the hydrogenated derivative of the curcuminoids from Curcumin C3 Complex®. It contains a minimum of 95% of Tetrahydrocurcuminoids (THCs) namely Tetrahydrocurcumin (THC), Tetrahydrodemethoxycurcumin (THDMC) and Tetrahydrobisdemethoxycurcumin (THBDMC). It is colourless, tasteless and aesthetically acceptable than curcuminoids (which gives yellow stain).
Curcumin and THC are the major constituents (≥ 75% of the total content) of the turmeric and reduced (hydrogenated) turmeric preparations, respectively. Tetrahydrocurcumin has higher physiological and pharmacological activities than its parent compound. The therapeutic interest for THC lies in its low toxicity and its beneficial biological activities
Keeping in pace with the developing science on the turmeric and its active compounds, Sabinsa presents you the next generation of curcuminoids as Curcumin C3 Reduct®.